With FDA decision penciled in for May, GSK powers ahead in RSV race with Pfizer

The last few weeks have seen GSK and Pfizer locked in a neck-and-neck race to see which company can get their respiratory syncytial virus (RSV) vaccines to market first. Now, it looks like the British Big Pharma may have the edge in the U.S., securing priority review status from the FDA and an estimated decision date of May 3.